Length of the second stage | <0.5 h (n = 534) | 0.5–2.0 h (n = 559) | ≥2.0 h (n = 81) | P-value |
---|---|---|---|---|
Mode of delivery | ||||
 Spontaneous vaginal (n = 1074) | 510 (95.5%) | 515 (92.1%) | 49 (60.5%) | <0.001 |
 Operative vaginal (n = 69) | 16 (3.0%) | 33 (5.9%) | 20 (24.7%) |  |
 Cesarean section (n = 31) | 8 (1.5%) | 11 (2.0%) | 12 (14.8%) |  |
Indications of OVD | ||||
 Prolonged second stage labor (n = 15) | 0 (0.0%) | 0 (0.0%) | 15 (75.0%) | <.0001 |
 Nonreassuring fetal heart rate (n = 51) | 16 (100.0) | 31 (93.9%) | 4 (20.0%) |  |
 Failed progress in labor (n = 3) | 0 (0.0%) | 2 (6.1%) | 1 (5.0%) |  |
Indications of cesarean | ||||
 Failed progress in labor (n = 14) | 0 (0.0%) | 6 (54.5%) | 8 (66.7%) | 0.048 |
 Nonreassuring fetal heart rate (n = 14) | 7 (87.5%) | 4 (36.4%) | 3 (25.0%) |  |
 Others (n = 3) | 1 (12.5%) | 1 (9.1%) | 1 (8.3%) |  |
Maternal outcomes | ||||
 PPH | 60 (11.2%) | 91 (16.3%) | 22 (27.2%) | <0.001 |
 Blood loss at 24 h (mL) | 315.0 (284.0–390.0) | 331.0 (290.0–453.5) | 420.0 (310.0–564.0) | <0.001 |
 Hb decreased (g/L) | 16.0 (9.0–23.0) | 18.0 (11.0–25.0) | 22.0 (14.0–30.0) | <0.001 |
 Oxytocin used (U) | 20.0 (10.0–20.0) | 20.0 (10.0–20.0) | 20.0 (20.0–40.0) | <0.001 |
 Transfusion | 14 (2.6%) | 18 (3.2%) | 4 (4.9%) | 0.508 |
 Uterine atony | 10 (1.9%) | 13 (2.3%) | 2 (2.5%) | 0.853 |
 Cervical lacerationa | 50 (9.5%) | 42 (7.7%) | 6 (8.7%) | 0.559 |
 Uterine rupture | 7 (1.3%) | 1 (0.2%) | 1 (1.2%) | 0.088 |
 ICU | 2 (0.4%) | 0 (0.0%) | 0 (0.0%) | 0.301 |
Neonatal outcomes | ||||
 1-min Apgar score ≤7 | 7 (1.3%) | 3 (0.5%) | 2 (2.5%) | 0.181 |
 5-min Apgar score ≤7 | 2 (0.4%) | 0 (0.0%) | 0 (0.0%) | 0.301 |
 Neonatal asphyxia | 6 (1.1%) | 2 (0.4%) | 1 (1.2%) | 0.308 |
 Assisted ventilation | 7 (1.3%) | 3 (0.5%) | 2 (2.5%) | 0.181 |
 NICU | 12 (2.2%) | 20 (3.6%) | 4 (4.9%) | 0.265 |
 Infection | 8 (1.5%) | 21 (3.8%) | 3 (3.7%) | 0.062 |